{"id":768830,"date":"2023-07-11T07:15:54","date_gmt":"2023-07-11T11:15:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/"},"modified":"2023-07-11T07:15:54","modified_gmt":"2023-07-11T11:15:54","slug":"silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/","title":{"rendered":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\nSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration<\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming peoples\u2019 lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (\u201cHansoh\u201d) following the achievement of two undisclosed preclinical milestones.<\/p>\n<p>\n\u201cWe are very pleased with the continued progress being made in our Hansoh Pharma collaboration,\u201d said Craig Tooman, President and CEO of Silence. \u201cToday\u2019s news follows the $10.0 million milestone payment we achieved in our AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline. We continue to be excited about the advancement of our siRNA technology in both partnered and proprietary programs.\u201d<\/p>\n<p>\nSilence and Hansoh entered a collaboration in October 2021 to develop siRNAs (\u201cshort interfering RNAs\u201d) leveraging Silence\u2019s proprietary mRNAi GOLD<sup>\u2122<\/sup> platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the first two targets in all territories except the China region. Hansoh has the exclusive option to license rights to those two targets in Greater China, Hong Kong, Macau and Taiwan, and global rights to the third target.<\/p>\n<p>\nHansoh made a $16 million upfront payment to Silence and the Company is eligible to receive up to $1.3 billion in development, regulatory and commercial milestones. Silence is also eligible to receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales. Today\u2019s announcement represents the second and third research milestone payments achieved under the collaboration. The Company achieved the first milestone payment for $2.0 million in April 2022.<\/p>\n<p><b>About Silence Therapeutics<\/b><\/p>\n<p>\nSilence Therapeutics is developing a new generation of medicines by harnessing the body&#8217;s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence&#8217;s proprietary mRNAi GOLD<sup>\u2122<\/sup> platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence&#8217;s wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DseWLk0Tijvb87pYYtHlfJBSxU-O0-uhbTanKn5RhA2rNJ_BGh5GwtTTFOolm5n2IgC_sZlfXwUjJf1q1KZQGqwMF9rpkGI9IXJVi3CKfXBhC7d9RDrI9bKFnvBa_D7yENo8TBNOrH81g_BaE5LBZTg%3D%3D&amp;esheet=53440250&amp;newsitemid=20230711209680&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;index=1&amp;md5=2156d7213d2e9d133199abf593b43adb\">https:\/\/www.silence-therapeutics.com\/<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company\u2019s cash runway and forecast operating cash flow, the Company\u2019s clinical and commercial prospects, regulatory approvals of the Company\u2019s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company\u2019s clinical trials and the anticipated timing or outcomes of data reports from the Company\u2019s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company&#8217;s current assumptions, beliefs, expectations, estimates and projections about its industry. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&#8217;s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company\u2019s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230711209680\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230711209680\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries:<\/b><\/p>\n<p><b>Silence Therapeutics plc<br \/>\n<\/b><br \/>Gem Hopkins, Head of IR and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@silence-therapeutics.com\">ir@silence-therapeutics.com<br \/>\n<\/a><br \/>Tel: +1 (646) 637-3208<\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Genetics Clinical Trials Other Health Biotechnology General Health Pharmaceutical Health Science Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230711209680\/en\/1834453\/3\/Silence-Logo-FINAL-rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming peoples\u2019 lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (\u201cHansoh\u201d) following the achievement of two undisclosed preclinical milestones. \u201cWe are very pleased with the continued progress being made in our Hansoh Pharma collaboration,\u201d said Craig Tooman, President and CEO of Silence. \u201cToday\u2019s news follows the $10.0 million milestone payment we achieved in our AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline. We continue to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768830","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming peoples\u2019 lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (\u201cHansoh\u201d) following the achievement of two undisclosed preclinical milestones. \u201cWe are very pleased with the continued progress being made in our Hansoh Pharma collaboration,\u201d said Craig Tooman, President and CEO of Silence. \u201cToday\u2019s news follows the $10.0 million milestone payment we achieved in our AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline. We continue to &hellip; Continue reading &quot;Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T11:15:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration\",\"datePublished\":\"2023-07-11T11:15:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/\"},\"wordCount\":790,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/\",\"name\":\"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-11T11:15:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk","og_description":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming peoples\u2019 lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (\u201cHansoh\u201d) following the achievement of two undisclosed preclinical milestones. \u201cWe are very pleased with the continued progress being made in our Hansoh Pharma collaboration,\u201d said Craig Tooman, President and CEO of Silence. \u201cToday\u2019s news follows the $10.0 million milestone payment we achieved in our AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline. We continue to &hellip; Continue reading \"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-11T11:15:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","datePublished":"2023-07-11T11:15:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/"},"wordCount":790,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/","name":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-11T11:15:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230711209680r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-4-million-in-research-milestone-payments-from-hansoh-pharma-collaboration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768830"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768830\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}